Terms: = Breast cancer AND CDK6, MGC59692, 1021, Q00534, ENSG00000105810, PLSTIRE AND Prognosis
37 results:
1. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative breast cancer by Recruiting EIF4A1 to Promote the m6A-Modified cdk6 Translation Initiation Process.
Xia T; Dai XY; Sang MY; Zhang X; Xu F; Wu J; Shi L; Wei JF; Ding Q
Adv Sci (Weinh); 2024 Jan; 11(1):e2305142. PubMed ID: 37983610
[TBL] [Abstract] [Full Text] [Related]
2. cdk6 is a novel predictive and prognosis biomarker correlated with immune infiltrates in multiple human neoplasms, including small cell lung carcinoma.
Li GS; Huang ZG; Li DM; Tang YL; Zheng JH; Yang L; Feng Y; Peng JX; Li JX; Tang YX; Zeng NY; Jin MH; Tian J; Liu J; Zhou HF; Chen G; Chen F
Funct Integr Genomics; 2023 Nov; 23(4):332. PubMed ID: 37950078
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Beta Blockers on breast cancer Incidence and prognosis.
Yang J; Zhang S; Jiang W
Clin Breast Cancer; 2023 Aug; 23(6):664-671.e21. PubMed ID: 37353431
[TBL] [Abstract] [Full Text] [Related]
4. Ethyl acetate extract of Antenoron Filiforme inhibits the proliferation of triple negative breast cancer cells via suppressing Skp2/p21 signaling axis.
Liao Y; Li S; An J; Yu X; Tan X; Gui Y; Wang Y; Huang L; Zhou S; Wang D
Phytomedicine; 2023 Jul; 116():154856. PubMed ID: 37187035
[TBL] [Abstract] [Full Text] [Related]
5. Wnt Signaling Pathway Collapse upon β-Catenin Destruction by a Novel Antimicrobial Peptide SKACP003: Unveiling the Molecular Mechanism and Genetic Activities Using breast cancer Cell Lines.
Selvarathinam K; Subramani P; Thekkumalai M; Vilwanathan R; Selvarajan R; Abia ALK
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770598
[TBL] [Abstract] [Full Text] [Related]
6. A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6.
Ji J; Zhang Z; He X; Pan G; Li G; Lv J; Xu Y; Xie M; Feng J; Wang W; Liu B; Ma J; Wang X
Anticancer Drugs; 2023 Aug; 34(7):803-815. PubMed ID: 36729405
[TBL] [Abstract] [Full Text] [Related]
7. nc-RNA-mediated high expression of cdk6 correlates with poor prognosis and immune infiltration in pancreatic cancer.
Zhao YX; Xu BW; Wang FQ; Jiang FY; Xu JW; Yu DX
Cancer Med; 2023 Feb; 12(4):5110-5123. PubMed ID: 36457244
[TBL] [Abstract] [Full Text] [Related]
8. Gene Expression Profiling between Patient Groups with High and Low Ki67 Levels after Short-term Preoperative Aromatase Inhibitor Treatment for breast cancer.
Kajiwara Y; Iwamoto T; Zhu Y; Kochi M; Shien T; Taira N; Doihara H; Toyooka S
Acta Med Okayama; 2022 Aug; 76(4):399-408. PubMed ID: 36123154
[TBL] [Abstract] [Full Text] [Related]
9. Time interval between the diagnosis of breast cancer and brain metastases impacts prognosis after metastasis surgery.
Michel A; Dinger TF; Santos AN; Pierscianek D; Darkwah Oppong M; Ahmadipour Y; Dammann P; Wrede KH; Hense J; Pöttgen C; Iannaccone A; Kimmig R; Sure U; Jabbarli R
J Neurooncol; 2022 Aug; 159(1):53-63. PubMed ID: 35672530
[TBL] [Abstract] [Full Text] [Related]
10. Identification of a five genes prognosis signature for triple-negative breast cancer using multi-omics methods and bioinformatics analysis.
Ma J; Chen C; Liu S; Ji J; Wu D; Huang P; Wei D; Fan Z; Ren L
Cancer Gene Ther; 2022 Nov; 29(11):1578-1589. PubMed ID: 35474355
[TBL] [Abstract] [Full Text] [Related]
11. ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis.
Zhang X; Mu X; Huang O; Wang Z; Chen J; Chen D; Wang G
BMC Cancer; 2022 Mar; 22(1):226. PubMed ID: 35236318
[TBL] [Abstract] [Full Text] [Related]
12. The molecular tumor burden index as a response evaluation criterion in breast cancer.
Yi Z; Ma F; Rong G; Liu B; Guan Y; Li J; Sun X; Wang W; Guan X; Mo H; Wang J; Qian H; Xu B
Signal Transduct Target Ther; 2021 Jul; 6(1):251. PubMed ID: 34230452
[TBL] [Abstract] [Full Text] [Related]
13. PFKFB4 Overexpression Facilitates Proliferation by Promoting the G1/S Transition and Is Associated with a Poor prognosis in Triple-Negative breast cancer.
Cai YC; Yang H; Shan HB; Su HF; Jiang WQ; Shi YX
Dis Markers; 2021; 2021():8824589. PubMed ID: 34211613
[TBL] [Abstract] [Full Text] [Related]
14. Serial circulating tumor DNA identification associated with the efficacy and prognosis of neoadjuvant chemotherapy in breast cancer.
Zhou Y; Xu Y; Wang C; Gong Y; Zhang Y; Yao R; Li P; Zhu X; Bai J; Guan Y; Xia X; Yang L; Yi X; Sun Q
Breast Cancer Res Treat; 2021 Aug; 188(3):661-673. PubMed ID: 34003409
[TBL] [Abstract] [Full Text] [Related]
15. 4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells.
Satriyo PB; Su CM; Ong JR; Huang WC; Fong IH; Lin CC; Aryandono T; Haryana SM; Deng L; Huang CC; Tzeng YM; Chao TY; Liu HW; Yeh CT
Toxicol Appl Pharmacol; 2021 Jul; 422():115493. PubMed ID: 33727089
[TBL] [Abstract] [Full Text] [Related]
16. Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive breast cancer.
De Angelis C; Fu X; Cataldo ML; Nardone A; Pereira R; Veeraraghavan J; Nanda S; Qin L; Sethunath V; Wang T; Hilsenbeck SG; Benelli M; Migliaccio I; Guarducci C; Malorni L; Litchfield LM; Liu J; Donaldson J; Selenica P; Brown DN; Weigelt B; Reis-Filho JS; Park BH; Hurvitz SA; Slamon DJ; Rimawi MF; Jansen VM; Jeselsohn R; Osborne CK; Schiff R
Clin Cancer Res; 2021 Sep; 27(17):4870-4882. PubMed ID: 33536276
[TBL] [Abstract] [Full Text] [Related]
17. Abemaciclib, a CDK4 and cdk6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract] [Full Text] [Related]
18. Machine Learning techniques in breast cancer prognosis prediction: A primary evaluation.
Boeri C; Chiappa C; Galli F; De Berardinis V; Bardelli L; Carcano G; Rovera F
Cancer Med; 2020 May; 9(9):3234-3243. PubMed ID: 32154669
[TBL] [Abstract] [Full Text] [Related]
19. MicroRNA-425-5p promotes breast cancer cell growth by inducing PI3K/AKT signaling.
Zhang LF; Zhang JG; Zhou H; Dai TT; Guo FB; Xu SY; Chen Y
Kaohsiung J Med Sci; 2020 Apr; 36(4):250-256. PubMed ID: 31688991
[TBL] [Abstract] [Full Text] [Related]
20. MiR-128-3p suppresses breast cancer cellular progression via targeting LIMK1.
Zhao J; Li D; Fang L
Biomed Pharmacother; 2019 Jul; 115():108947. PubMed ID: 31078043
[TBL] [Abstract] [Full Text] [Related]
[Next]
